ABSTRACT
The objective of the study was to observe the antimicrobial resistance of AmpC [beta]-lactamase producing E. coli. Six hundred and seventy E. coli were isolated from 20,257 various pathological samples collected from The Children's Hospital and Institute of Child Health, Lahore, Pakistan. The isolates showed resistance to ceftazidime which were further examined for AmpC [beta]-lactamase activity by Disc Potentiation method. There were 670 isolates of E. coli out of which 85 [12.6%] were AmpC [beta]-lactamase producers. Risk factors like intravenous line [76.5%], endotracheal tube [22.4%], surgery [12.9%] and urinary catheters [7.1%] were found to be associated with infection caused by AmpC [beta]-lactamase producing E. coli. Antimicrobial resistance pattern revealed that AmpC producing E. coli were highly resistant to coamoxiclav, ceftazidime, cefotaxime, cefuroxime, cefixime, ceftriaxone and cefoxitin [100% each]. Least resistance was observed against sulbactam-cefoperazone [14.1%], cefepime [7.1%], piperacillin-tazobactam [5.9%] and none of the isolates were resistant to imipenem and meropenem. The minimum use of invasive devices and strict antibiotic policies can reduce the spread of AmpC [beta]-lactamase producing E. coli
ABSTRACT
The emergence of ESBL producing Enterobacter cloacae in clinical isolates is posing a serious threat for treating nosocomial infections. The aim of the study was to determine the frequency of extended spectrum beta-lactamase [ESBL] producing Enterobacter cloacae and to compare the phenotypic methods used for the characterization of ESBL producing strains. This cross sectional observational study was conducted during April 2011 to March 2012 at Microbiology department of The Children's Hospital and Institute of Child Health, Lahore. A total number of 20,257 various clinical samples were analyzed during the study period. Enterobacter cloacae were identified using API 20E system and ESBL detection was carried out using double-disk synergy test [DDST] and CLSI confirmatory test. Enterobacter cloacae were isolated from 221 samples, out of which 33 [14.93%] were ESBL producers and 188 [85.07%] were non-ESBL producers. The gender distribution of ESBL producing Enterobacter cloacae was 21 [63.6%] in males and 12 [36.4%] in females. Highest frequency [63%] of ESBL producing Enterobacter cloacae was detected in blood samples. Comparison of DDST and CLSI confirmatory test showed that 25 [75.75%] isolates were characterized by DDST and 33 [100%] using CLSI confirmatory test. The present study shows moderately high frequency of ESBL producing Enterobacter cloacae among children. DDST was found to be less efficient in ESBL detection as compared to CLSI confirmatory test
Subject(s)
Humans , Male , Female , beta-Lactamases , Phenotype , Child , Cross-Sectional StudiesABSTRACT
The production of AmpC beta-lactamases is one of the common mechanisms of beta-lactam drugs resistance. AmpC beta-lactamases produce resistance to various clinically important cephalosporins. The purpose of this study was to determine the frequency of AmpC beta-lactamase producing Escherichia coli and its occurrence in different clinical samples. This cross sectional observational study was conducted during April 2011 to March 2012 in the Microbiology Department of The Children's Hospital and Institute of Child Health, Lahore. A total number of 20,257 pathological samples like blood, cerebrospinal fluid [CSF], urine, pus, endotracheal tube [ETT], pleural fluid, sputum and urinary catheters were analyzed during the study period. E. coli were identified using API 20E system and resistance to cefoxitin was used as a screening test followed by disk potentiation as confirmatory test for AmpC beta-lactamases. E. coli were isolated in 670 samples out of which 85 [12.6%] were AmpC beta-lactamase producers. The gender distribution of patients with AmpC beta-lactamase producing E. coli was 52 [61.2%] in males and 33 [38.8%] in females. The occurrence rate of AmpC beta-lactamase producing E. coli in clinical samples was highest in blood 45 [52.9%].The present study shows moderately high frequency of AmpC beta-lactamase producing E. coli which may increase morbidity and mortality among children. Earlier detection of AmpC beta-lactamases will decrease the morbidity rate of AmpC beta-lactamase producing E. coli infection.